Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 3/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2834230 | 0.99 | MEN1 (0.39) | MEN1KMT2AKDM4EINSRIGF1R | |
| SCHEMBL457402 | 0.88 | KMT2A (0.52) | MEN1KMT2AKDM4EJAK2PLA2G2A | |
| SCHEMBL29750185 | 0.87 | MEN1 (0.44) | MEN1KMT2AKDM4EINSRIGF1R | |
| SCHEMBL456750 | 0.87 | MEN1 (0.44) | MEN1KMT2AKDM4EINSRIGF1R | |
| Methane SCHEMBL13736906 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EINSRIGF1R | |
| Hydrochloric Acid SCHEMBL574759 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EINSRIGF1R | |
| Bromide SCHEMBL13737447 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4EINSRIGF1R | |
| Trifluoroacetic Acid SCHEMBL4717787 | 0.85 | MEN1 (0.38) | MEN1KMT2AINSRIGF1RMET | |
| SCHEMBL3944260 | 0.83 | ELANE (0.41) | MEN1KMT2AINSRIGF1RMET | |
| Hydrochloric Acid SCHEMBL4718164 | 0.82 | ELANE (0.41) | MEN1KMT2AINSRIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | claimed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | claimed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | claimed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | claimed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| EP-2086542-A1 | TOPICAL FORMULATIONS | Helperby Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | claimed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| WO-2008056151-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | claimed |
| EP-3228314-B1 | SULOCTIDIL FOR USE TO TREAT MICROBIAL INFECTIONS | HELPERBY THERAPEUTICS LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10265373-B2 | Pharmaceutical composition and method of treating a microbial infection with sulcotidil | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| WO-2018162928-A1 | METHOD FOR RESTORING EFFICACY OF AN ANTIBACTERIAL AGENT | HELPERBY THERAPEUTICS LIMITED (GB) | 2018-09-13 | — | — | WO | disclosed |
| US-9789101-B2 | Methods and compositions for treating microbial infection using pyrroloquinone | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3228314-A1 | VASODILATOR FOR USE TO TREAT MICROBIAL INFECTIONS | Helperby Therapeutics Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | disclosed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| WO-2012032360-A2 | NOVEL USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | MEN1 1394/4885KMT2A 2403/4885KDM4E 1494/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | MEN1 1394/4885KMT2A 2403/4885KDM4E 1494/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | MEN1 1394/4885KMT2A 2403/4885KDM4E 1494/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | MEN1 2763/4885KMT2A 4302/4885KDM4E 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.